Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul>
<li>Sacra estimates that Chobani generated $3.6B in trailing twelve months revenue as of September 2025, up 22% year-over-year and up from $3.0B for 2024.</li>
<li>Chobani raised a $650M equity round in October 2025 at a $20B post-money valuation, implying a ~5.6x revenue multiple on TTM sales, above traditional CPG peers.</li>
<li>The ~$1.7B manufacturing expansion program is expected to produce negative free cash flow through 2026, with a return to positive free cash flow projected for 2027.</li>
</ul>


Sacra estimates that Chobani generated $3.6B in trailing twelve months revenue as of September 2025, up 22% year-over-year and up from $3.0B for 2024.
Chobani raised a $650M equity round in October 2025 at a $20B post-money valuation, implying a ~5.6x revenue multiple on TTM sales, above traditional CPG peers.
The ~$1.7B manufacturing expansion program is expected to produce negative free cash flow through 2026, with a return to positive free cash flow projected for 2027.


<ul><li>Chobani hit $3.6B in TTM revenue in September 2025, up ~22% YoY, valued at $20B after a $650M equity round in October 2025.</li><li>Expanding from Greek yogurt into a five-category portfolio via Chobani oat milk (2019) & creamer (2019) and by acquiring cold brew brand La Colombe for $900M (2023) & DTC frozen meals brand Daily Harvest for $600M (2025).</li><li>With ~12% of American adults reporting they've used a medication like Ozempic, the Chobani family of products has emerged as a perfect fit for the GLP-1 dietary spec, with Greek yogurt for protein density needed to preserve lean mass, La Colombe cold brew & creamer for the GLP-1 fatigue, and Daily Harvest frozen smoothies and bowls for the fiber needed to manage the gastrointestinal symptoms.</li></ul>

Chobani hit $3.6B in TTM revenue in September 2025, up ~22% YoY, valued at $20B after a $650M equity round in October 2025.Expanding from Greek yogurt into a five-category portfolio via Chobani oat milk (2019) & creamer (2019) and by acquiring cold brew brand La Colombe for $900M (2023) & DTC frozen meals brand Daily Harvest for $600M (2025).With ~12% of American adults reporting they've used a medication like Ozempic, the Chobani family of products has emerged as a perfect fit for the GLP-1 dietary spec, with Greek yogurt for protein density needed to preserve lean mass, La Colombe cold brew & creamer for the GLP-1 fatigue, and Daily Harvest frozen smoothies and bowls for the fiber needed to manage the gastrointestinal symptoms.

United States

Food company producing Greek yogurt, oat milk, and creamers with natural ingredients

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chobani (CHOBANI US)

Primer: Chobani - 03 Mar 2026

Food company producing Greek yogurt, oat milk, and creamers with natural ingredients

Sacra

$3.6B/year Atkins Of Yogurt

TL;DR: Founded by Turkish immigrant dairy farmer Hamdi Ulukaya who bought a defunct Kraft yogurt plant with an SBA loan in 2005, Chobani...

Sacra

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)